Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07418749 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

StatusRecruiting
PhasePhase 3
Started2026-03-30
View on ClinicalTrials.gov ↗

Amendment history

2026-04-03
Study Status, Contacts/Locations v1
Recruitment opened
Start dateestimated 2026-03→confirmed 2026-03-30
Study sitesdetails revised at 1 of 1 site
2026-02-11
Original filing
The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
Trial Details
NCT Number NCT07418749
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Recurrent Cervical Cancer, Metastatic Cervical Cancer
Enrollment 398 participants
Start Date 2026-03-30
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06